UNICHEM LABORATORIES LTD.

Unichem Laboratories Ltd has responded to a stock exchange query regarding a significant price movement in its securities. The company stated that it has consistently complied with SEBI's disclosure requirements and is unaware of any undisclosed material information that could have caused the price surge. Unichem attributes the price increase to market-driven factors and confirms its commitment to ongoing compliance with listing regulations.

Unichem Laboratories Ltd. has informed shareholders, particularly those without registered email addresses, about accessing the Annual Report for FY 2025-26. In compliance with SEBI regulations, the company has sent letters providing a web-link to the report. The 63rd Annual General Meeting is scheduled for August 11, 2026. The communication also serves as a reminder for shareholders holding physical securities to update KYC details and dematerialize shares as per recent SEBI mandates, to ensure eligibility for payments like dividends. Shareholders are encouraged to update their email addresses for continued access to important information and to support green initiatives.

Unichem Laboratories Ltd has issued letters to shareholders without registered email addresses, providing a web-link to access the Annual Report for FY 2025-26. This action complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The 63rd Annual General Meeting is scheduled for August 11, 2026, via video conferencing. The company also reminds shareholders to update KYC details and dematerialize physical securities as per recent SEBI mandates, highlighting the electronic payment requirement for non-compliant folios from April 1, 2024.

Unichem Laboratories Ltd has announced its 63rd Annual General Meeting (AGM) will be held on Tuesday, August 11, 2026, at 3:30 p.m. IST via Video Conference/Other Audio-Visual Means. The meeting will cover ordinary business, including the adoption of audited standalone and consolidated financial statements for the financial year 2025-26. Key special business includes the re-appointment of Mr. Pabitrakumar Bhattacharyya as Managing Director & CEO for a further three-year term and the ratification of remuneration for the Cost Auditors, Kishore Bhatia & Associates, for the financial year ending March 31, 2027.

Unichem Laboratories Ltd has released its Business Responsibility and Sustainability Report for FY 2025-26. The report details that 100% of the company's turnover is derived from the manufacture and sale of pharmaceutical products, specifically Allopathic Medicines. A significant portion, 97.6%, of the total turnover comes from exports. The company serves diverse therapeutic areas and markets globally, primarily selling to its wholly-owned subsidiaries. The report also provides employee data, including a breakdown of permanent and non-permanent employees and workers by gender, and details on differently-abled employees. Women representation on the Board of Directors is 16.67%. Turnover rates for permanent employees and workers over the past three fiscal years are also disclosed.

Unichem Laboratories Ltd has released its Annual Report for the financial year 2025-26, along with the Business Responsibility & Sustainability Report and the Notice of the 63rd Annual General Meeting (AGM). The AGM is scheduled for August 11, 2026, to be held via video conference. The report details financial highlights, management discussion, corporate governance, and sustainability initiatives. Shareholders can participate in remote e-voting from August 7 to August 10, 2026. The Annual Report is available on the company's website and sent electronically to registered members.

Unichem Laboratories Ltd has announced the closure of its trading window for dealing in the company's shares. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut for designated persons, directors, insiders, and their immediate relatives starting July 1, 2026. It is scheduled to reopen 48 hours after the financial results for the quarter ended June 30, 2026, are publicly disclosed. This measure is standard practice to prevent potential insider trading during periods when material non-public information might be available.

Equity Intelligence India Pvt Ltd, through its portfolio management clients and EQ India Fund, has acquired 3,00,000 shares of Unichem Laboratories Ltd. This transaction represents a 0.43% stake, reducing their pre-acquisition holding of 0.98% to 0.56% post-acquisition. The acquisition was made on the open market on June 11, 2026. The total diluted share capital of Unichem Laboratories Ltd after the acquisition stands at 7,09,05,750 equity shares.

Equity Intelligence India Pvt Ltd, through its portfolio management clients and EQ India Fund, has acquired 300,000 shares of Unichem Laboratories Ltd. This transaction, executed on June 11, 2026, represents a 0.43% stake. Prior to this acquisition, Equity Intelligence held approximately 0.98% of the company's shares. Following the purchase, their total holding in Unichem Laboratories stands at 394,375 shares, or 0.56% of the total diluted share capital. The acquisition was made through open market transactions.

Unichem Laboratories responded to an exchange query regarding a significant increase in its share trading volume. The company clarified that it has consistently made timely disclosures as per SEBI (LODR) Regulations, 2015. It attributed the surge in volume to purely market-driven forces, stating it has no further comments to offer on the matter. Unichem reiterated its commitment to ongoing regulatory compliance by continuing to make necessary disclosures.